


Appendix A

Claim Amendments

1. (Currently amended) ~~Compounds~~ A compound of formula 1



in which

R1 is phenyl,

phenyl substituted by R3 and/or R4,

naphthalenyl,

naphthalenyl substituted by R5 and/or R6,

aryl1,

aryl1 substituted by R7 and/or R8,

R9,

R10 or

R11,

R2 is phenyl,

phenyl substituted by R12 and/or R13,


naphthalenyl,

naphthalenyl substituted by R14 and/or R15,

aryl2,

aryl2 substituted by R16 and/or R17

or a radical selected from



R3 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-

yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy,
 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-
 azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-
 4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy,
 $-(CH_2)_n-N(R_{31})R_{32}$, $-CH_2CH(OH)CH_2N(R_{31})R_{32}$ or $-O-(CH_2)_m-$
 $N(R_{31})R_{32}$ wherein

R₃₁ is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl,
 and

R₃₂ is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl
 or wherein

R₃₁ and R₃₂ together and with inclusion of the nitrogen
 atom to which they are bonded form a pyrrolidin-,
 piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-
 4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-
 [1,4]diazepan-, morpholin-, thiomorpholin- or an
 azepan-ring,

n is an integer from 0 to 4,

m is an integer from 2 to 4,

R₄ is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl,
 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominately~~
predominately substituted by fluorine, amino or mono- or
 di-1-4C-alkylamino,

R5 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R_{31})R_{32}$, $-CH_2CH(OH)CH_2N(R_{31})R_{32}$ or $-O-(CH_2)_m-N(R_{31})R_{32}$,

R6 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominantly~~


predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

Aryl1 is furanyl, thiophenyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl or dibenzofuranyl, R7 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or ~~predominately~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-

yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy,
 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-
 azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-
 4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy,
 $-(CH_2)_n-N(R_{31})R_{32}$, $-CH_2CH(OH)CH_2N(R_{31})R_{32}$ or $-O-(CH_2)_m-$
 $N(R_{31})R_{32}$,

R8 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl,
 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominately~~
predominately substituted by fluorine, amino or mono- or
 di-1-4C-alkylamino,

R9 is unsubstituted pyrrolyl, pyrazolyl, imidazolyl,
 indolyl, indazolyl, benzimidazolyl or benztriazolyl, or
 a radical selected from




wherein

R91 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-
 alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy

completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R_{31})R_{32}$, $-CH_2CH(OH)CH_2N(R_{31})R_{32}$ or $-O-(CH_2)_m-N(R_{31})R_{32}$,

R92 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R10 is a radical selected from




wherein

R101 is 1-4C-alkyl, 2,2,2-trifluoroethyl or 3,3,3-trifluoropropyl,

R102 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R11 is a radical selected from



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, $-(CH_2)_p-N(R112)R113$ or $-CH_2CH(OH)CH_2N(R112)R113$, wherein R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or wherein

R112 and R113 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

Aryl2 is furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl,

benzimidazolyl, benzo[1,3]dioxolyl,

2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl,

quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl,

phthalazinyl, indanyl, indolyl or indazolyl,

R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

~~and the salts of these compounds~~ or a salt thereof, with

the proviso that the following compounds are excluded

4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-{4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-{4-[6-(2-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-
4-methyl-benzenesulfonamide,

N-{4-[6-(4-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-
4-methyl-benzenesulfonamide,

N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-
phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

N-(3-{6-[4-(Toluene-4-sulfonylamino)-phenylamino]-
pyrimidin-4-yl}-phenyl)-acetamide,

N-{4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-
phenyl}-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-
ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-
ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

N-{4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,


N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide, and

4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide.

2. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is phenyl,
phenyl substituted by R3 and/or R4,
naphthalenyl or
naphthalenyl substituted by R5 and/or R6,
R2 is phenyl,
phenyl substituted by R12 and/or R13,
naphthalenyl,
naphthalenyl substituted by R14 and/or R15,
aryl₂,
aryl₂ substituted by R16 and/or R17
or a radical selected from



R3 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl,

aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy or benzyloxy,

R4 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R5 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy or benzyloxy,

R6 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or

~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

Aryl2 is furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,

R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted

by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, ~~and the salts of these compounds~~ or a salt thereof, with

the proviso that the following compounds are excluded

4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-{4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-{4-[6-(2-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-(3-{6-[4-(Toluene-4-sulfonylamino)-phenylamino]-pyrimidin-4-yl}-phenyl)-acetamide,

N-{4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide, and

N-{4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide.

3. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3-

acetylphenyl, 4-acetylphenyl, 3-cyanophenyl, 4-phenoxyphenyl or naphthalen-1-yl,

R2 is phenyl, phenyl substituted by R12 and/or R13, thiophenyl, naphthalenyl or 5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-yl,

R12 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine or 1-4C-alkoxycarbonyl,

R13 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

~~and the salts of these compounds~~ or a salt thereof, with the

proviso that the following compounds are excluded

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide, and

N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide.

4. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-acetylphenyl or naphthalen-1-yl,

R2 is 2-fluorophenyl, 3-fluorophenyl, 3,4-difluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluorophenyl, 3-chloro-4-methylphenyl, 3-bromophenyl, 3-methylphenyl, 4-methylphenyl, 4-isopropylphenyl, 4-trifluoromethylphenyl, 4-methoxyphenyl, 4-cyanophenyl or 5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-yl,

~~and the salts of these compounds~~ or a salt thereof, with

the proviso that the following compounds are excluded

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-

benzenesulfonamide and

4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-


phenyl]-benzenesulfonamide.

5. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is phenyl substituted by R3 and/or R4 or naphthalenyl substituted by R5 and/or R6,

R2 is phenyl,

phenyl substituted by R12 and/or R13,
 naphthalenyl,
 naphthalenyl substituted by R14 and/or R15,
 aryl2,
 aryl2 substituted by R16 and/or R17
 or a radical selected from



R3 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-

(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R31)R32$, $-CH_2CH(OH)CH_2N(R31)R32$ or $-O-(CH_2)_m-N(R31)R32$, wherein

R31 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and R32 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl or wherein

R31 and R32 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

n is an integer from 0 to 4,

m is an integer from 2 to 4,

R4 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R5 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-

4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R31)R32$, $-CH_2CH(OH)CH_2N(R31)R32$ or $-O-(CH_2)_m-N(R31)R32$,

R6 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

Aryl2 is furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,

R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, ~~and the salts of these compounds~~ or a salt thereof.

6. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is phenyl substituted in para or meta position by R3 or phenyl substituted in para and meta position by R3 and R4,

R2 is phenyl substituted by R12 and/or R13,

R3 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-

azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R31)R32$, $-CH_2CH(OH)CH_2N(R31)R32$ or $-O-(CH_2)_m-N(R31)R32$, wherein

R31 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and R32 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl or wherein

R31 and R32 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

n is an integer from 1 to 4,

m is an integer from 2 to 4,

R4 is fluorine, methyl or methoxy,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or

~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, ~~and the salts of these compounds~~ or a salt thereof.

7. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is phenyl substituted in para or meta position by R3,

R2 is phenyl substituted by R12 and/or R13,

R3 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R31)R32$, $-CH_2CH(OH)CH_2N(R31)R32$ or $-O-(CH_2)_m-N(R31)R32$, wherein

R31 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R32 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl
or wherein

R31 and R32 together and with inclusion of the nitrogen
atom to which they are bonded form a pyrrolidin-,
piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-
4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-
[1,4]diazepan-, morpholin-, thiomorpholin- or an
azepan-ring,

n is an integer from 1 to 4,

m is an integer from 2 to 4,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl,
trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is
completely or ~~predominantly~~ predominately substituted
by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-
1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-
alkoxy, 1-4C-alkoxy which is completely or
~~predominantly~~ predominately substituted by fluorine, 1-
4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
~~and the salts of these compounds~~ or a salt thereof.

8. (Currently amended) ~~Compounds~~ A compound of formula 1
according to claim 1 in which

R1 is phenyl substituted in para position by R3 or phenyl substituted in para position by R3 and in meta position by R4,

R2 is phenyl substituted by R12 and/or R13,

R3 is morpholin-4-ylmethyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, 2-morpholin-4-ylethoxy, 3-morpholin-4-ylpropoxy, 4-methylpiperazin-1-ylmethyl, 4-methylpiperazin-1-ylethyl, 4-methylpiperazin-1-ylpropyl, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 1-methylpiperidin-4-ylmethoxy, 1-methylpiperidin-4-ylmethyl, 1-methylpiperidin-4-ylethyl, 1-methylpiperidin-4-ylpropyl, 2-(1-methylpiperidin-4-yl)ethoxy, 3-(1-methylpiperidin-4-yl)propoxy, pyrrolidin-1-ylpropyl, pyrrolidin-1-ylethyl, pyrrolidin-1-ylmethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethoxy, piperidin-1-ylmethyl, piperidin-1-ylethyl, piperidin-1-ylpropyl, 2-(piperidin-1-yl)ethoxy, 3-(piperidin-1-yl)propoxy,

R4 is fluorine, methyl or methoxy,

R12 is fluorine, chlorine, cyano, methyl, isopropyl, trifluoromethyl or methoxy,

R13 is fluorine or chlorine,

~~and the salts of these compounds~~ or a salt thereof.

9. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which
- R1 is phenyl substituted in para or meta position by R3,
- R2 is phenyl substituted by R12 and/or R13,
- R3 is morpholin-4-ylmethyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, 2-morpholin-4-ylethoxy, 3-morpholin-4-ylpropoxy, 4-methylpiperazin-1-ylmethyl, 4-methylpiperazin-1-ylethyl, 4-methylpiperazin-1-ylpropyl, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 1-methylpiperidin-4-ylmethoxy, 1-methylpiperidin-4-ylmethyl, 1-methylpiperidin-4-ylethyl, 1-methylpiperidin-4-ylpropyl, 2-(1-methylpiperidin-4-yl)ethoxy, 3-(1-methylpiperidin-4-yl)propoxy, pyrrolidin-1-ylpropyl, pyrrolidin-1-ylethyl, pyrrolidin-1-ylmethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethoxy, piperidin-1-ylmethyl, piperidin-1-ylethyl, piperidin-1-ylpropyl, 2-(piperidin-1-yl)ethoxy, 3-(piperidin-1-yl)propoxy,
- R12 is fluorine, chlorine, cyano, methyl, isopropyl, trifluoromethyl or methoxy,
- R13 is fluorine or chlorine,
- ~~and the salts of these compounds~~ or a salt thereof.

10. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is phenyl substituted in para position by R3 or phenyl substituted in para position by R3 and in meta position by R4,

R2 is 2-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl, 2-fluoro-4-methylphenyl, 2-fluoro-4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methylphenyl, 4-methoxyphenyl or 3-chloro-4-fluorophenyl,

R3 is 2-morpholin-4-ylethoxy, 3-morpholin-4-ylpropoxy, 4-methylpiperazin-1-ylethoxy, 4-methylpiperazin-1-ylpropoxy, morpholin-4-ylmethyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, 1-methylpiperidin-4-ylmethoxy, 2-(1-methylpiperidin-4-yl)ethoxy, 4-methylpiperazin-1-ylethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethoxy or 3-pyrrolidin-1-ylpropyl,

R4 is fluorine,

~~and the salts of these compounds~~ or a salt thereof.

11. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is phenyl substituted in para or meta position by R3,

R2 is 2-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl, 4-methylphenyl, 4-methoxyphenyl or 3-chloro-4-fluorophenyl,

R3 is 2-morpholin-4-ylethoxy, 3-morpholin-4-ylpropoxy, 4-methylpiperazin-1-ylethoxy, 4-methylpiperazin-1-ylpropoxy, morpholin-4-ylmethyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, 1-methylpiperidin-4-ylmethoxy, 2-(1-methylpiperidin-4-yl)ethoxy, 4-methylpiperazin-1-ylethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethoxy or 3-pyrrolidin-1-ylpropyl,

~~and the salts of these compounds~~ or a salt thereof.


12. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is aryl1,
aryl1 substituted by R7 and/or R8,
R9 or
R10,

R2 is phenyl,
phenyl substituted by R12 and/or R13,
naphthalenyl,
naphthalenyl substituted by R14 and/or R15,
aryl2,

aryl2 substituted by R16 and/or R17

or a radical selected from



Aryl1 is furanyl, thiophenyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl or dibenzofuranyl, R7 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-

pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R_{31})R_{32}$, $-CH_2CH(OH)CH_2N(R_{31})R_{32}$ or $-O-(CH_2)_m-N(R_{31})R_{32}$, wherein

R₃₁ is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and R₃₂ is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl or wherein


R₃₁ and R₃₂ together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

n is an integer from 0 to 4,

m is an integer from 2 to 4,

R8 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominately~~ predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R9 is unsubstituted pyrrolyl, pyrazolyl, imidazolyl, indolyl, indazolyl, benzimidazolyl or benztriazolyl, or a radical selected from




wherein

R91 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or ~~predominately~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-

1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R31)R32$, $-CH_2CH(OH)CH_2N(R31)R32$ or $-O-(CH_2)_m-N(R31)R32$,

R92 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R10 is a radical selected from



wherein

R101 is 1-4C-alkyl, 2,2,2-trifluoroethyl or 3,3,3-trifluoropropyl,

R102 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or ~~predominantly~~ predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

Aryl2 is furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,

R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, ~~and the salts of these compounds~~ or a salt thereof with the

proviso that the following compounds are excluded

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide, and

4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide.

13. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is pyrid-3-yl, pyrid-4-yl, 2-methyl-2,3-dihydrobenzofuran-5-yl, benzo[1,3]dioxol-5-yl, 1-methyl-1H-pyrrol-3-yl, 4-methyl-thiophen-2-yl, 1-methyl-1H-pyrrol-2-yl, 1H-indol-5-yl, 1-methyl-1H-indol-3-yl, 1-methyl-1H-indol-5-yl, dibenzofuran-4-yl or 3,5-dimethyl-isoxazol-4-yl,

R2 is phenyl substituted by R12 and/or R13 or naphthalenyl,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

~~and the salts of these compounds~~ or a salt thereof with the proviso that the following compounds are excluded

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-
4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-
benzenesulfonamide, and
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-
benzenesulfonamide.

14. (Currently amended) ~~Compounds~~ A compound of formula 1

according to claim 1 in which

R1 is 2-methyl-2,3-dihydrobenzofuran-5-yl, benzo[1,3]-
dioxol-5-yl, 1-methyl-1H-pyrrol-3-yl, 4-methyl-thiophen-
2-yl, 1-methyl-1H-pyrrol-2-yl, 1H-indol-5-yl, 1-methyl-
1H-indol-3-yl or 1-methyl-1H-indol-5-yl,

R2 is phenyl substituted by R12 and/or R13 or naphthalenyl,

R12 is fluorine, chlorine, cyano, methyl, trifluoromethyl or
methoxy,

R13 is fluorine, chlorine or methoxy,

~~and the salts of these compounds~~ or a salt thereof with the
proviso that the compound

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-
4-methyl-benzenesulfonamide is excluded.

15. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is 2-methyl-2,3-dihydrobenzofuran-5-yl, 1-methyl-1H-pyrrol-3-yl or 4-methylthiophen-2-yl, and

R2 is 2,6-difluorophenyl,

or

R1 is 1H-indol-5-yl, and

R2 is 2,6-difluorophenyl, 2,4-difluorophenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl or 3-fluorophenyl,

or

R1 is 1-methyl-1H-indol-5-yl or 1-methyl-1H-indol-3-yl, and

R2 is 2,6-difluorophenyl, 2-fluorophenyl or 4-methoxyphenyl,

or

R1 is 1-methyl-1H-indol-5-yl, and

R2 is 2-fluoro-4-methylphenyl,

~~and the salts of these compounds~~ or a salt thereof.

16. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

either

R1 is 2-methyl-2,3-dihydrobenzofuran-5-yl, 1-methyl-1H-pyrrol-3-yl or 4-methylthiophen-2-yl, and

R2 is 2,6-difluorophenyl,

or

R1 is 1H-indol-5-yl, and

R2 is 2,6-difluorophenyl, 2,4-difluorophenyl, 2-fluorophenyl or 3-fluorophenyl,

or

R1 is 1-methyl-1H-indol-5-yl or 1-methyl-1H-indol-3-yl, and

R2 is 2,6-difluorophenyl, 2-fluorophenyl or 4-methoxyphenyl,

~~and the salts of these compounds~~ or a salt thereof.

17. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is R11,

R2 is phenyl,

phenyl substituted by R12 and/or R13,


naphthalenyl,

naphthalenyl substituted by R14 and/or R15,


aryl2,

aryl2 substituted by R16 and/or R17

or a radical selected from



R11 is a radical selected from



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, $-(CH_2)_p-N(R112)R113$ or $-CH_2CH(OH)CH_2N(R112)R113$, wherein R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl,

and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or
wherein

R112 and R113 together and with inclusion of the nitrogen
atom to which they are bonded form a pyrrolidin-,
piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-
4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-
[1,4]diazepan-, morpholin-, thiomorpholin- or an
azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl,
trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely
or ~~predominantly~~ predominately substituted by fluorine,
amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl,
trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is
completely or ~~predominantly~~ predominately substituted
by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-
1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-
alkoxy, 1-4C-alkoxy which is completely or
~~predominantly~~ predominately substituted by fluorine, 1-
4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

Aryl2 is furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,

R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,


R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, ~~and the salts of these compounds~~ or a salt thereof.

18. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is R11,

R2 is phenyl substituted by R12 and/or R13,

R11 is a radical selected from



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-

3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl,

-(CH₂)_p-N(R112)R113 or -CH₂CH(OH)CH₂N(R112)R113, wherein

R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl,

and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or

wherein

R112 and R113 together and with inclusion of the nitrogen

atom to which they are bonded form a pyrrolidin-,

piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-

4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-

[1,4]diazepan-, morpholin-, thiomorpholin- or an

azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl,

trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely

or ~~predominantly~~ predominately substituted by fluorine,

amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl,

trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is

completely or ~~predominantly~~ predominately substituted

by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-

1-4C-alkylamino,


R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, ~~and the salts of these compounds~~ or a salt thereof.

19. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is R11,

R2 is phenyl substituted by R12 and/or R13,

R11 is a radical selected from



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, $-(CH_2)_p-N(R112)R113$ or $-CH_2CH(OH)CH_2N(R112)R113$, wherein

R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl,
and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or
wherein

R112 and R113 together and with inclusion of the nitrogen
atom to which they are bonded form a pyrrolidin-,
piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-
4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-
[1,4]diazepan-, morpholin-, thiomorpholin- or an
azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl,
trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely
or ~~predominantly~~ predominately substituted by fluorine,
amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl,
trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is
completely or ~~predominantly~~ predominately substituted
by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-
1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-
alkoxy, 1-4C-alkoxy which is completely or


~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, ~~and the salts of these compounds~~ or a salt thereof.

20. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is R11,

R2 is phenyl substituted by R12 and/or R13,

R11 is a radical selected from



wherein

R111 is pyrrolidin-1-ylethyl, pyrrolidin-1-ylpropyl, piperidin-1-ylethyl, piperidin-1-ylpropyl, azepan-1-yl-ethyl, azepan-1-ylpropyl, (4-methyl-piperazin-1-yl)ethyl, (4-methyl-piperazin-1-yl)propyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, (1-methyl-piperidin-4-yl)propyl, (1-methyl-piperidin-4-yl)ethyl, (1-methyl-piperidin-4-yl)methyl, dimethylaminoethyl, dimethylaminopropyl, dimethylaminobutyl,

diethylaminoethyl, diethylaminopropyl or
diethylaminobutyl,

R114 is hydrogen or fluorine,

R12 is fluorine, chlorine, cyano, methyl, isopropyl,
trifluoromethyl or methoxy,

R13 is fluorine or chlorine,


~~and the salts of these compounds~~ or a salt thereof.

21. (Currently amended) ~~Compounds~~ A compound of formula 1
according to claim 1 in which

R1 is R11,

R2 is 2-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl,
2,4-difluorophenyl, 4-methylphenyl, 4-methoxyphenyl, 3-
fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, or 3-
chloro-4-fluorophenyl,

R11 represents the following radical



wherein

R111 is pyrrolidin-1-ylethyl, pyrrolidin-1-ylpropyl, (4-methyl-
piperazin-1-yl)ethyl, (4-methyl-piperazin-1-yl)propyl,
(1-methyl-piperidin-4-yl)ethyl, (1-methyl-piperidin-4-

yl)methyl, dimethylaminoethyl, dimethylaminopropyl,
diethylaminopropyl or diethylaminobutyl,
~~and the salts of these compounds~~ or a salt thereof.

22. (Canceled).

23. (Currently amended) A pharmaceutical composition
comprising ~~Pharmaceutical compositions containing~~ one or
more compounds according to claim 1, or a pharmaceutically
acceptable salt thereof, together with ~~the usual~~
~~pharmaceutical auxiliaries and/or excipients~~ a
pharmaceutically acceptable auxiliary and/or excipient.

24. (Canceled)

25. (Currently amended) A method for treating acute or
chronic rejection of organ or tissue allo- or xenografts,
atherosclerosis, vascular occlusion due to vacular injury,
~~such as~~ angioplasty, restenosis, hypertension, heart
failure, chronic obstructive pulmonary disease, ~~CNS~~
~~diseases such as Alzheimer~~ Alzheimer's disease, ~~[[or]]~~
amyotrophic lateral sclerosis, cancer, infectious diseases,
~~such as~~ AIDS, septic shock ~~[[or]]~~ adult respiratory

distress syndrome, ischemia/reperfusion injury, [[e.g.]] myocardial infarction, stroke, gut ischemia, renal failure, [[or]] hemorrhage shock, [[or]] traumatic shock, ~~T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma, [[or]] inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, and further eczematous dermatitis, seborrhoeic dermatitis ~~dermatitises, seborrhoeic dermatitis~~), inflammatory eye diseases, [[e.g.]] Sjogren's syndrome, keratoconjunctivitis, [[or]] uveitis, inflammatory bowel disease, Crohn's disease, [[or]] ulcerative colitis in a patient comprising administering to said patient a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.~~

26. (Currently amended) A compound selected from the group consisting of

4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-{4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-{4-[6-(2-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-(3-{6-[4-(Toluene-4-sulfonylamino)-phenylamino]-pyrimidin-4-yl}-phenyl)-acetamide,

N-{4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-

phenyl]-benzenesulfonamide,

N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-

methyl-benzenesulfonamide,

N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-

4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-

phenyl]-benzenesulfonamide,

and salts thereof

~~or a salt thereof for use in the treatment of diseases.~~

27. (Currently amended) ~~Pharmaceutical~~ A pharmaceutical

composition comprising ~~containing~~ one or more compounds

selected from the group consisting of

4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-

phenyl]-benzenesulfonamide,

N-{4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-

phenyl}-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-

benzenesulfonamide,

4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-

phenyl]-benzenesulfonamide,

N-{4-[6-(2-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-
4-methyl-benzenesulfonamide,

N-{4-[6-(4-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-
4-methyl-benzenesulfonamide,

N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-
phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

N-(3-{6-[4-(Toluene-4-sulfonylamino)-phenylamino]-
pyrimidin-4-yl}-phenyl)-acetamide,

N-{4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-
phenyl}-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-
ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-
ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

N-{4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

and pharmaceutically acceptable salts ~~or a salt~~ thereof

together with a pharmaceutically acceptable auxiliary

and/or excipient ~~the usual pharmaceutical auxiliaries~~
~~and/or excipients.~~

28. (Canceled)

29. (Currently amended) A method for treating acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vascular injury, ~~such as~~ angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, ~~CNS diseases such as Alzheimer~~ Alzheimer's disease, ~~[[or]]~~ amyotrophic lateral sclerosis, cancer, infectious diseases, ~~such as~~ AIDS, septic shock ~~[[or]]~~ adult respiratory distress syndrome, ischemia/reperfusion injury, ~~[[e.g.]]~~ myocardial infarction, stroke, gut ischemia, renal failure, ~~[[or]]~~ hemorrhage shock, ~~[[or]]~~ traumatic shock, ~~T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g.~~ rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II ~~and the disorders associated therewith,~~ ~~respiratory diseases such as~~ asthma, ~~[[or]]~~ inflammatory lung injury, inflammatory liver injury, inflammatory

glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, ~~inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, and further eczematous dermatitis, seborrhoeic dermatitis dermatitises, seborrhoeic dermatitis)~~, inflammatory eye diseases, [[e.g.]] Sjogren's syndrome, keratoconjunctivitis, [[or]] uveitis, inflammatory bowel disease, Crohn's disease, [[or]] ulcerative colitis in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of 4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide, N-{4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide, 4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide, 4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide, N-{4-[6-(2-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-
4-methyl-benzenesulfonamide,

N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-
phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

N-(3-{6-[4-(Toluene-4-sulfonylamino)-phenylamino]-
pyrimidin-4-yl}-phenyl)-acetamide,

N-{4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-
phenyl}-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-
ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-
ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-
methyl-benzenesulfonamide,

N-{4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-
phenyl}-4-methyl-benzenesulfonamide,

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-
4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-
benzenesulfonamide,

N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-
phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-
benzenesulfonamide,

N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-
methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-
phenyl]-benzenesulfonamide,

N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-
methyl-benzenesulfonamide,

N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-
4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-
phenyl]-benzenesulfonamide

~~or a salt thereof~~ and pharmaceutically acceptable salts
thereof.

30. (Currently amended) A compound selected from the group
consisting of

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-
4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-
benzenesulfonamide,

N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-
phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-
benzenesulfonamide,

N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-
methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-
phenyl]-benzenesulfonamide,

N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-
methyl-benzenesulfonamide,

N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-
4-methyl-benzenesulfonamide, [[and]]

4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-
phenyl]-benzenesulfonamide,

~~or a salt~~ and salts thereof ~~for use in the treatment of~~
diseases.

31. (Currently amended) ~~Pharmaceutical compositions~~
~~containing~~ A pharmaceutical composition comprising one or
more compounds selected from the group consisting of
N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-
4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-
benzenesulfonamide,
N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-
phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-
benzenesulfonamide,
N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-
methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-
phenyl]-benzenesulfonamide,
N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-
methyl-benzenesulfonamide,
N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-
4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-
phenyl]-benzenesulfonamide,
and pharmaceutically acceptable salts or a salt thereof
together with a pharmaceutically acceptable auxiliary

~~and/or excipient the usual pharmaceutical auxiliaries~~
~~and/or excipients.~~

32. (Cancel)

33. (Currently amended) A method for treating acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vascular injury, ~~such as~~ angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, ~~CNS diseases such as Alzheimer~~ Alzheimer's disease, ~~[[or]]~~ amyotrophic lateral sclerosis, cancer, infectious diseases, ~~such as~~ AIDS, septic shock ~~[[or]]~~ adult respiratory distress syndrome, ischemia/reperfusion injury, ~~[[e.g.]]~~ myocardial infarction, stroke, gut ischemia, renal failure, ~~[[or]]~~ hemorrhage shock, ~~[[or]]~~ traumatic shock, ~~T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g.~~ rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II ~~and the disorders associated therewith,~~ ~~respiratory diseases such as~~ asthma, ~~[[or]]~~ inflammatory lung injury, inflammatory liver injury, inflammatory

glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, ~~inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, and further eczematous dermatitis, seborrhoeic dermatitis dermatitises, seborrhoeic dermatitis)~~, inflammatory eye diseases, [[e.g.]] Sjogren's syndrome, keratoconjunctivitis, [[or]] uveitis, inflammatory bowel disease, Crohn's disease, [[or]] ulcerative colitis in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide, 4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide, N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide, 4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide, N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-

phenyl]-benzenesulfonamide,

N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-

methyl-benzenesulfonamide,

N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-

4-methyl-benzenesulfonamide, **[[and]]**

4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-

phenyl]-benzenesulfonamide,

~~or a salt thereof~~ and pharmaceutically acceptable salts thereof.

10/586121

Appendix B

Specification Amendment


Please insert the following into the specification at
page 1, line 1:

-- This application was filed under 35 U.S.C. 371 as a
national stage of PCT/EP2005/050206, filed January 19,
2005. --

Appendix C

Abstract of the Disclosure

Compounds of a certain formula 1



in which R1 and R2 have the meanings indicated in the description are novel kinase inhibitors.